Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 10/20 | 0.51 |
| ▸ | RORC | P51449 | 6/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708172 | 0.94 | RORB (0.46) | RORBRORCTACR1GRM2 | |
| SCHEMBL4707011 | 0.89 | IDO1 (0.44) | TACR1ALDH1A1GAAIDO1TDO2 | |
| SCHEMBL4707172 | 0.88 | RORB (0.46) | RORBRORCGRM2ALDH1A1GAA | |
| SCHEMBL4708046 | 0.88 | RORB (0.42) | RORBRORCTACR1GRM2 | |
| SCHEMBL4707969 | 0.88 | CDC7 (0.42) | RORBRORCTACR1GRM2ALDH1A1 | |
| SCHEMBL4707650 | 0.87 | RORB (0.41) | RORBRORCGRM2ALDH1A1GAA | |
| SCHEMBL4708690 | 0.87 | RORB (0.40) | RORBRORCTACR1ALDH1A1GAA | |
| SCHEMBL4705384 | 0.86 | TACR1 (0.39) | RORBRORCTACR1ALDH1A1GAA | |
| SCHEMBL4707863 | 0.86 | IDH1 (0.44) | RORBRORCTACR1GRM2 | |
| SCHEMBL4638919 | 0.85 | TACR1 (0.48) | RORBRORCTACR1GRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-01-21 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-01-25 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| US-9782397-B2 | Treatment of corneal neovascularization | IRBM SCIENCE PARK S.P.A. (IT) | 2017-10-10 | — | — | US | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320994-B2 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1501809-B1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | ELI LILLY COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501809-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091226-A1 | TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239786-A1 | Triazole derivatives as tachykinin receptor antagonists | TACR1, TACR2, BDKRB1 | RORB 2614/4885RORC 2723/4885TACR1 1/4885 |
| US-20230134843-A1 | TREATMENT OF STEM CELL DEFICIENCY | KIT, TACR1, MRGPRX2 | RORB 664/4885RORC 824/4885TACR1 2/4885 |
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OPRK1, OPRL1, KLKB1 | RORB 1923/4885RORC 2315/4885TACR1 18/4885 |
| US-20180021327-A1 | TREATMENT OF CORNEAL NEOVASCULARIZATION | KDR, BAK1, FLT1 | RORB 3261/4885RORC 4019/4885TACR1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.